TrialClinical genitourinary cancer2013

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.

Roberto Pili et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.